BACKGROUND: Transmission of antiretroviral drug-resistant strains of HIV-1 has a major impact on the success of HIV treatment regimens in most countries where antiretroviral therapy (ART) is available. It is now recommended that HIV-1 drug resistance be monitored in order to recommend appropriate therapy for infected ART-naïve individuals, or when choosing a new regimen for those patients not responding to ART. Commercial assays for the analysis of HIV-1 genotypic resistance have been approved by the US FDA. In China, several laboratories and research enterprises have been developing related assays, but at present, no systematic standardization or quality control for genotypic resistance assays has been established in China. A national reference panel is needed to evaluate and control the quality of HIV-1 genotype resistance assays in China. METHODS: A panel of five HIV-1 stocks (G1, G2, G3, G4, and G5) with well-characterized drug resistance was used to evaluate the resistance-mutation inclusivity of HIV-1 clades prevalent in China. Six samples (GS1-GS6) were used to evaluate the limit of detection (LOD) for the viral load levels, and five samples (GSS1-GSS3, GSS5, and GSS6) were used to evaluate the LOD for the percentages of mutant species within the range of detection. The samples were evaluated by five separate laboratories using one or two methods each, generating seven datasets in all. RESULTS: In samples G1-G5, which were used to evaluate inclusivity of HIV-1 clades, 92.86-100%, 16.67-83.33% and 4.17-8.33% of the most, intermediately, and least common resistance mutations, respectively, were reported by the seven datasets. For the LOD samples, four of the seven datasets reported correct resistance mutations in samples with minimal viral loads of >2 x 10(3) copies/mL, as well as in samples with >40% of mutants and viral loads of about 1 x 10(4) copies/mL; the other three tests did not amplify the target region or identify the mutants. CONCLUSIONS: The results were quite variable between different tests. The panel of HIV-1 genotypic resistance could be used as a control for resistance testing in China.
BACKGROUND: Transmission of antiretroviral drug-resistant strains of HIV-1 has a major impact on the success of HIV treatment regimens in most countries where antiretroviral therapy (ART) is available. It is now recommended that HIV-1 drug resistance be monitored in order to recommend appropriate therapy for infected ART-naïve individuals, or when choosing a new regimen for those patients not responding to ART. Commercial assays for the analysis of HIV-1 genotypic resistance have been approved by the US FDA. In China, several laboratories and research enterprises have been developing related assays, but at present, no systematic standardization or quality control for genotypic resistance assays has been established in China. A national reference panel is needed to evaluate and control the quality of HIV-1 genotype resistance assays in China. METHODS: A panel of five HIV-1 stocks (G1, G2, G3, G4, and G5) with well-characterized drug resistance was used to evaluate the resistance-mutation inclusivity of HIV-1 clades prevalent in China. Six samples (GS1-GS6) were used to evaluate the limit of detection (LOD) for the viral load levels, and five samples (GSS1-GSS3, GSS5, and GSS6) were used to evaluate the LOD for the percentages of mutant species within the range of detection. The samples were evaluated by five separate laboratories using one or two methods each, generating seven datasets in all. RESULTS: In samples G1-G5, which were used to evaluate inclusivity of HIV-1 clades, 92.86-100%, 16.67-83.33% and 4.17-8.33% of the most, intermediately, and least common resistance mutations, respectively, were reported by the seven datasets. For the LOD samples, four of the seven datasets reported correct resistance mutations in samples with minimal viral loads of >2 x 10(3) copies/mL, as well as in samples with >40% of mutants and viral loads of about 1 x 10(4) copies/mL; the other three tests did not amplify the target region or identify the mutants. CONCLUSIONS: The results were quite variable between different tests. The panel of HIV-1 genotypic resistance could be used as a control for resistance testing in China.
Authors: D C Sayer; S Land; L Gizzarelli; M French; G Hales; S Emery; F T Christiansen; E M Dax Journal: J Clin Microbiol Date: 2003-01 Impact factor: 5.948
Authors: Lisa Ross; Ronan Boulmé; Robin Fisher; Jaime Hernandez; Allison Florance; Jean-Claude Schmit; Vanessa Williams Journal: AIDS Res Hum Retroviruses Date: 2005-11 Impact factor: 2.205
Authors: Sabine Yerly; Viktor von Wyl; Bruno Ledergerber; Jürg Böni; Jörg Schüpbach; Philippe Bürgisser; Thomas Klimkait; Martin Rickenbach; Laurent Kaiser; Huldrych F Günthard; Luc Perrin Journal: AIDS Date: 2007-10-18 Impact factor: 4.177
Authors: Annemarie M J Wensing; David A van de Vijver; Gioacchino Angarano; Birgitta Asjö; Claudia Balotta; Enzo Boeri; Ricardo Camacho; Maire-Laure Chaix; Dominique Costagliola; Andrea De Luca; Inge Derdelinckx; Zehava Grossman; Osamah Hamouda; Angelos Hatzakis; Robert Hemmer; Andy Hoepelman; Andrzej Horban; Klaus Korn; Claudia Kücherer; Thomas Leitner; Clive Loveday; Eilidh MacRae; Irina Maljkovic; Carmen de Mendoza; Laurence Meyer; Claus Nielsen; Eline L Op de Coul; Vidar Ormaasen; Dimitris Paraskevis; Luc Perrin; Elisabeth Puchhammer-Stöckl; Lidia Ruiz; Mika Salminen; Jean-Claude Schmit; Francois Schneider; Rob Schuurman; Vincent Soriano; Grzegorz Stanczak; Maja Stanojevic; Anne-Mieke Vandamme; Kristel Van Laethem; Michela Violin; Karin Wilbe; Sabine Yerly; Maurizio Zazzi; Charles A Boucher Journal: J Infect Dis Date: 2005-08-15 Impact factor: 5.226
Authors: Diana D Huang; Susan H Eshleman; Donald J Brambilla; Paul E Palumbo; James W Bremer Journal: J Clin Microbiol Date: 2003-07 Impact factor: 5.948
Authors: Bernard Masquelier; Krishnan Bhaskaran; Deenan Pillay; Robert Gifford; Eric Balestre; Louise Bruun Jørgensen; Court Pedersen; Lia van der Hoek; Maria Prins; Claudia Balotta; Benedetta Longo; Claudia Kücherer; Gabriele Poggensee; Marta Ortiz; Carmen de Mendoza; John Gill; Hervé Fleury; Kholoud Porter Journal: J Acquir Immune Defic Syndr Date: 2005-12-15 Impact factor: 3.731
Authors: Sally Land; Julian Zhou; Philip Cunningham; Annette H Sohn; Thida Singtoroj; David Katzenstein; Marita Mann; David Sayer; Rami Kantor Journal: J Int AIDS Soc Date: 2013-07-10 Impact factor: 5.396